top of page

Adults With the Most Oxybenzone in Their Urine Had 40% Higher Odds of Alcohol-Related Liver Disease, Study of US Adults Finds

2 minutes ago
7 min read

Australian Sunscreen Council Expert Group


Oxybenzone was one of three chemicals, out of 40 tested, with the strongest associations with alcohol-related liver disease in a study of 13,472 US adults, with oxybenzone measured in 4,313 of them. In women, the odds were 44.6% higher per standard-deviation rise in urine oxybenzone.


Photo illustration: a crop of the 2026 Journal of Translational Medicine paper on oxybenzone and alcohol-related liver disease odds in US adults; the authors note the cross-sectional design precludes causal inference.

A study of US national health survey data found adults with the highest urine levels of oxybenzone had 40% higher odds of alcohol-related liver disease than those with the lowest, after adjusting for age, sex, weight and other factors (odds ratio 1.40, 95% CI 1.15–1.72) (Ma et al., 2026, pp. 1, 7). The oxybenzone in this study is the same oxybenzone found in some sunscreens sold in Australia, where it is a permitted sunscreen ingredient (Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2026, item 3645).


Oxybenzone, also called benzophenone-3, was one of three chemicals, out of 40 tested, with the strongest associations. The paper, which studies "metabolism-disrupting agents" (MDAs), reports: "Three MDAs demonstrated robust positive associations", listing oxybenzone as "benzophenone-3 (BP-3; OR: 1.40, 95% CI: 1.15–1.72)" (Ma et al., 2026, p. 1). The authors write that "as a rigorous sensitivity check for multiple comparisons, the robust positive associations observed for BMA, PFHxS, and BP-3 remained highly statistically significant even when evaluated against the stringent Bonferroni-adjusted threshold" (Ma et al., 2026, p. 5).


In women, each standard-deviation rise in urine oxybenzone came with 44.6% higher odds of alcohol-related liver disease (odds ratio 1.446, 95% CI 1.309–1.599); in men, the result was not statistically significant (Ma et al., 2026, p. 10).


What the study found


The study, by Ma and colleagues, was published in the Journal of Translational Medicine in July 2026. It used data on 13,472 adults from the US National Health and Nutrition Examination Survey, 2005 to 2016, with oxybenzone measured in 4,313 of them (Ma et al., 2026, p. 1; Supplementary Table S1). Alcohol-related liver disease was defined from a doctor's diagnosis, or from raised liver enzymes together with heavy drinking (Ma et al., 2026, p. 3).


After full adjustment, the odds of alcohol-related liver disease were higher in every quarter of urine oxybenzone above the lowest: 27%, 35% and 40% higher (Ma et al., 2026, p. 7). The authors write: "Benzophenone-3 (BP-3) exhibited a non-linear pattern characterized by positive associations at low-to-moderate exposures that plateaued at higher concentrations" (Ma et al., 2026, p. 14). The authors reported "significantly stronger associations among females" for oxybenzone and related chemicals (Ma et al., 2026, p. 8).


Before adjustment for age, sex and other factors, the top-versus-bottom result was not statistically significant (odds ratio 1.08, 95% CI 0.91–1.28); the third quarter was (odds ratio 1.26, 95% CI 1.07–1.50) (Ma et al., 2026, p. 7). The authors write: "This study has limitations. The cross-sectional design precludes causal inference" (Ma et al., 2026, p. 16). Oxybenzone was measured once, in a single urine sample, and the authors note that "reverse causation cannot be excluded" (Ma et al., 2026, p. 16).


The paper says the chemical classes it tested reach people "via water, food packaging, personal care products, and air" (Ma et al., 2026, p. 2). The authors conclude: "These findings emphasize the need for integrating environmental exposure assessments into ALD risk stratification and highlight the potential for regulatory action to mitigate these risks" (Ma et al., 2026, p. 17). ALD is alcohol-related liver disease.


What other regulators have done


The European Union restricts oxybenzone, listed in its rules as Benzophenone-3, as a UV filter in cosmetic products under Commission Regulation (EU) 2022/1176 (European Commission, 2022, p. 52, recital 8). The regulation records that a call for data was launched in 2019 "in light of concerns related to potential endocrine disrupting properties of Benzophenone-3 and Octocrylene, when used as UV filters in cosmetic products" (European Commission, 2022, p. 51, recital 2), and the European Commission concluded that "there is potential risk to human health arising from the use of Benzophenone-3 and Octocrylene as UV filters in cosmetic products in the concentrations currently allowed" (European Commission, 2022, p. 52, recital 8).


A May 2025 safety review by Australia's Therapeutic Goods Administration (TGA) says: "Benzophenone, an important impurity and degradant of octocrylene, is considered to be genotoxic, carcinogenic and shown to disrupt endocrine signalling." (TGA, 2025a, p. 54 of 74).


The United States Food and Drug Administration (FDA) noted in 2019 "studies indicating that oxybenzone is absorbed through the skin to a greater extent than previously understood and can lead to significant systemic exposure, as well as data showing the presence of oxybenzone in human breast milk, amniotic fluid, urine, and blood plasma" (U.S. Food and Drug Administration [FDA], 2019, p. 6206). In 2021 the FDA wrote: "Given the available data showing significant transdermal absorption and systemic availability of oxybenzone, as well as the potential for endocrine activity, we propose that sunscreens containing oxybenzone are not GRASE", GRASE meaning generally recognised as safe and effective (FDA, 2021, p. 44). Transdermal means through the skin.


Non-nano zinc oxide is the only broad-spectrum UV filter that is reef safe and Generally Recognized As Safe and Effective (GRASE) by the US FDA (National Oceanic and Atmospheric Administration [NOAA], n.d.; National Park Service [NPS], n.d.; FDA, 2019, p. 6206; Beasley & Meyer, 2010; Hanrahan, 2012). On its own it protects across the full UVA and UVB range, including long UVA (Beasley & Meyer, 2010; Hanrahan, 2012).


The United States Food and Drug Administration (FDA) now classifies bemotrizinol as generally recognized as safe and effective for over-the-counter sunscreens, under conditions set in its June 2026 final order (FDA, 2026, p. 8). The final order says "FDA concludes that bemotrizinol is GRASE for use as an active ingredient in OTC sunscreen drug products under the conditions set forth in Section IX of this document, and other applicable requirements." (FDA, 2026, p. 8). In its December 2025 proposed order, the FDA described bemotrizinol as exhibiting "high photostability and broad-spectrum coverage across the UVB (280 to 320 nanometers (nm)) and UVA (320 to 400 nm) ranges" (FDA, 2025, p. 5).


Other sun protection


Sunscreen is one part of sun protection. Cancer Council Australia says "Sunscreen is not a suit of armour and should be used with the other four sun protection measures" (Cancer Council Australia, n.d.). Its advice is to wear sun-protective clothing: "Choose clothing that covers as much skin as possible (think shirts with long sleeves)." Some clothing "may carry an ultraviolet protection factor (UPF), which is a guarantee of how much UV protection a fabric provides" (Cancer Council Australia, n.d.). Add a "broad-brimmed hat", "Seek shade" and wear "close-fitting wraparound sunglasses, that meet Australian Standards" (Cancer Council Australia, n.d.). The Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) says "There is more to sun protection than just sunscreen. No sunscreen provides complete protection against UVR" (ARPANSA, n.d.).



About the Australian Sunscreen Council


The Australian Sunscreen Council is a registered Australian charity dedicated to improving the health of everyday Australians through UV education, research and evidence-based sun safety initiatives.


As Australia’s peak industry body for sunscreen safety, the Council works with scientists, medical professionals, industry experts and policymakers to advance sunscreen safety, support independent research, improve public understanding of UV exposure and promote stronger public-health standards.


ABN 64 692 134 982


Australian Sunscreen Council Expert Group


The Council is supported by an Expert Group and may draw on advice from one or more members depending on the subject matter of a particular article, submission or publication. Members listed by the Council include (Australian Sunscreen Council, n.d.):


  • Dr Craig Downs, Executive Director, Haereticus Environmental Laboratory

  • Dr Russell Hills, cosmetic and laser dermatologist and Mohs specialist

  • Dr Denis Dudley, obstetrician-gynaecologist and endocrinologist

  • Dr Abhinandan “Rocky” Chowdhury, toxicologist

  • Dr Leslie Laquieze, sunscreen testing and photoprotection

  • Mgr. Mehrdad Mirzaei, pharmacist and photoprotection researcher

  • Joseph DiNardo, cosmetic toxicologist

  • Dr Alan Jones, skin cancer physician

  • Camila Biato Stopa, MSc, cosmetic scientist and pharmacist




Acknowledgment


Grok was used in the creation of this article. Always read the sunscreen label and use only as directed. Sunscreen is only one part of sun protection. Avoid prolonged sun exposure and wear protective clothing, hats, and eyewear.



References


Australian Radiation Protection and Nuclear Safety Agency. (n.d.). Sun protection using sunscreens. Retrieved November 1, 2026, from https://www.arpansa.gov.au/understanding-radiation/radiation-sources/more-radiation-sources/sun-protection-sunscreen


Australian Sunscreen Council. (n.d.). Scientific experts in sunscreen safety. Retrieved October 24, 2026, from https://www.australiansunscreencouncil.org/scientific-experts-sunscreen-safety


Beasley, D. G., & Meyer, T. A. (2010). Characterization of the UVA protection provided by avobenzone, zinc oxide, and titanium dioxide in broad-spectrum sunscreen products. American Journal of Clinical Dermatology, 11(6), 413–421. https://doi.org/10.2165/11537050-000000000-00000


Cancer Council Australia. (n.d.). Protect your skin in five simple steps. Retrieved November 1, 2026, from https://www.cancer.org.au/save-your-skin/five-sunsmart-steps


European Commission. (2022). Commission Regulation (EU) 2022/1176 of 7 July 2022 amending Regulation (EC) No 1223/2009 of the European Parliament and of the Council as regards the use of certain UV filters in cosmetic products. Official Journal of the European Union, L 183, 51–53. https://eur-lex.europa.eu/eli/reg/2022/1176/oj


Hanrahan, J. R. (2012). Sunscreens. Australian Prescriber, 35(5), 148–151. https://doi.org/10.18773/austprescr.2012.068


Ma, L., Zhang, J., Wei, J., Bian, W., Bo, T., Shao, S., Li, X., Zhao, J., & Yao, Z. (2026). The hidden effects of metabolism-disrupting agents on alcohol-related liver disease risk: An integrated epidemiological, machine learning, and network toxicology analysis. Journal of Translational Medicine, 24, Article 1328. https://doi.org/10.1186/s12967-026-08673-2


National Oceanic and Atmospheric Administration. (n.d.). Skincare chemicals and marine life. National Ocean Service. Retrieved October 10, 2026, from https://oceanservice.noaa.gov/news/sunscreen-corals.html


National Park Service. (n.d.). Sunscreen. U.S. Department of the Interior. Retrieved October 10, 2026, from https://www.nps.gov/subjects/oceans/sunscreen.htm


Therapeutic Goods Administration. (2025a, May). Safety review of seven active sunscreen ingredients (Version 1.0) [Released under FOI 26-2156, Document 4]. https://www.tga.gov.au/sites/default/files/2026-06/FOI%2026-2156.PDF


Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2026 (Cth). F2026L01382. https://www.legislation.gov.au/F2026L01382/latest/text


U.S. Food and Drug Administration. (2019, February 26). Sunscreen drug products for over-the-counter human use (Proposed rule, 84 Fed. Reg. 6204; Docket No. FDA-1978-N-0018). Federal Register. https://www.govinfo.gov/content/pkg/FR-2019-02-26/pdf/2019-03019.pdf


U.S. Food and Drug Administration. (2021, September 24). Proposed order (OTC000008): Amending over-the-counter (OTC) monograph M020: Sunscreen drug products for OTC human use. OTC Monographs@FDA. https://www.accessdata.fda.gov/scripts/cder/omuf/index.cfm


U.S. Food and Drug Administration. (2025, December 12). Proposed administrative order (OTC000039): Amending over-the-counter monograph M020: Sunscreen drug products for over-the-counter human use (Docket No. FDA-2025-N-6494; 90 Fed. Reg. 57765). https://www.accessdata.fda.gov/drugsatfda_docs/omuf/Order/supportDoc/OTC000039/Internal_Documents/2025.12.09%20ProposedOrder_BemotrizinolOTC000039_090026f88e15dab6.pdf


U.S. Food and Drug Administration. (2026, June 10). Final administrative order (OTC000039): Amending over-the-counter monograph M020: Sunscreen drug products for over-the-counter human use, and related information [Corrected version, August 10, 2026] (Docket No. FDA-2025-N-6494; 91 Fed. Reg. 35220). https://www.accessdata.fda.gov/drugsatfda_docs/omuf/Order/OTC000039_Final_Administrative_Order.pdf


bottom of page